Regulation of tau pathology by the microglial fractalkine receptor. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010 Oct 6;68(1):19-31. PubMed Abstract

	Comments on Paper and Primary News

	Primary News: Paper Alert: Fractalkine Receptor Hits Aβ, Tau, in Opposite Ways Comment by: Bruce Lamb
	Submitted 5 October 2010 \| Permalink	Posted 6 October 2010
	As best I am aware, this is the first set of studies to examine the effects of the same signaling pathway on the two different AD pathologies independently. The fact that we observed completely opposite effects of CX3CR1 deficiency on Aβ and Tau pathologies suggests that therapeutics strategies aimed at this (and related) pathways may have opposing effects depending upon the stage of disease progression and prevalence of the different brain pathologies. Given recent evidence from imaging and biomarker studies that suggest Aβ and Tau pathologies are differentially induced over a 10-20 year period of time, this provides additional impetus for designing therapeutic strategies and clinical trials aimed at specific stages of disease progression. View all comments by Bruce Lamb

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:
Antibodies used in this study:
MAPT Antibodies: Mouse monoclonal antibodies AT8, AT180 (Pierce) and Tau5 (Invitrogen); PHF-1, CP13, TG3 (all provided by Peter Davies, Albert Einstein College of Medicine).
Inflammatory Markers: Rabbit polyclonal antibody against ionized calcium binding adaptor molecule 1 (Iba1) (Wako); rat monoclonal antibody against CD68 (Serotec). Mouse monoclonal antibodies against CD11b/Mac-1 (Chemicon/Millipore) and iNOS (Transduction Laboratories).
Other Antibodies: Mouse monoclonal antibody against GAPDH; rabbit polyclonal antibodies against activated ATF-2 phospho thr71, total p38 MAPK, and activated p38 MAPK (phospho thr180/tyr182) were from Cell Signaling; mouse monoclonal antibody against Cdk5 regulators p35/p25 (Millipore), rabbit monoclonal antibody against GSK3b-phospho ser9 (Millipore); rabbit monoclonal antibody to PP2A C-subunit (52F8) (Cell Signaling).